| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 900 WINTER ST., WALTHAM | /s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson | 06 Feb 2026 | 0001730048 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALKS | Ordinary Shares | Award | +25,352 | +44% | 83,092 | 05 Feb 2026 | Direct | F1 | ||
| transaction | ALKS | Ordinary Shares | Tax liability | $250,082 | -7,454 | -9% | $33.55 | 75,638 | 05 Feb 2026 | Direct |
| Id | Content |
|---|---|
| F1 | These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 23, 2023 with a three-year performance period that ended on December 31, 2025 (the "2023 PRSUs"). The vesting of this portion of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier and represents the final vesting event under the 2023 PRSUs. |